Morepen Laboratories Limited's share price soared on Tuesday, March 18, 2025, following the launch of Empamore, a groundbreaking treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). The stock surged 9.7% to ₹47 apiece on the National Stock Exchange (NSE), reflecting strong investor confidence in the company's latest pharmaceutical innovation.
With over 101 million diabetes patients in India, Empamore aims to provide high-quality, affordable treatment, empowering millions to manage their health effectively. If you're looking to capitalise on such promising developments, now might be the right time to buy shares online and benefit from the potential growth of the pharmaceutical sector.
What wakes Empamore a game-changer?
Empamore contains Empagliflozin, a widely recognised SGLT2 inhibitor used in diabetes management. Morepen Laboratories manufactures this API at its USFDA-approved facilities and holds a European DMF, ensuring global quality standards. The product lineup includes:
With India's prediabetes cases nearing 136 million and the diabetes market projected to grow at a Compound Annual Growth Rate (CAGR) of 10.9%, Empamore's launch is well-timed to meet rising healthcare demands. As the pharmaceutical industry expands, investors seeking exposure to this sector can explore opportunities to buy shares online for potential long-term gains.
Investing in Morepen Laboratories
Morepen's 40-year legacy of pharmaceutical excellence and cost-effective alternatives to leading brands make it a strong contender in the market. The company's commitment to affordable healthcare is evident, with Empamore priced nearly 90% lower than existing brands.
For those looking to diversify their portfolio, the pharmaceutical sector presents lucrative possibilities. The rising demand for diabetes treatment, coupled with Morepen's strategic expansion, makes it an attractive option.
Summing up
Morepen Laboratories' shares surged 9.7% after launching Empamore, a cost-effective diabetes treatment. The company's USFDA-approved production and European DMF accreditation enhance its credibility. With India's diabetes cases rising, the demand for affordable treatments is expected to grow. Investors can seize this opportunity and buy shares online to benefit from the pharmaceutical industry's expansion.
As of 10:30 AM on March 18, 2025, Morepen Laboratories' shares were trading at ₹47.10 on the NSE, reflecting a 9.94% rise today.
For android only